Elevated levels are recapitulated in high grade glioma tissue biopsies and plasma samples in which poor clinical outcome potentiates harnessing IGFBP‐2 as outcome predictor and biomarker.20, 21, 22. The gene discussed is IGFBP2; the disease is central nervous system cancer.